marked.bio

SERM · small molecule

lasofoxifene

1 active trials, targeting ER. Not approved for any biomarker on marked.bio yet.

Also known as Fablyn.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ESR1 mutation 1 3 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of lasofoxifene.

  1. LeonaBio 1

Trials

1 of 3 trials shown

  1. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    Recruiting Phase 3 LeonaBio Started 2023Primary completion 2027-04 NCT05696626

    lasofoxifeneabemaciclib FDAfulvestrant

    At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast can…

    ESR1 mutationMetastatic Breast Cancer